All Things Newz
Business

Bluebird bio’s gene therapy for blood disorder gets FDA panel backing


Article content

Bluebird bio’s treatment for a

rare blood disorder received backing from advisers to the U.S.

Food and Drug Administration on Friday, in a vote of confidence

in gene therapies and bolstering the company beset by regulatory

setbacks.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Maju

Samuel)



Source link

Related posts

More grain must be shifted from Ukraine’s silos, says U.N. official

Nikkei tracks Wall Street’s robust finish, tech shares shine

Box Office: ‘Bullet Train’ Arrives With So-So $30.1 Million Debut, ‘Easter Sunday’ Stumbles